Immunotherapies for Cancer
Oxford BioTherapeutics (OBT) is a clinical stage oncology company committed to the discovery and development of novel therapies for various cancer types.
OBT's approach, based on our proprietary immune-oncology and antibody-drug conjugate pipelines, is to re-engage and recruit the body's immune system to attack cancer cells. We are therefore able to provide targeted treatment strategies to patients most in need, including those who have failed to respond to conventional treatments. Our first therapy, a drug for relapsed/refractory Acute Myeloid Leukemia (AML), entered Ph I testing in Europe in 2012 in collaboration with the Menarini group.
To help bring about this much awaited transformation in the cancer therapy landscape, we have built one of the world’s largest integrated oncology immune cell surface protein libraries. This, together with our dedicated team of international immuno-oncology experts and our broad clinical alliances, have led to our discovery of multiple never-before identified cancer-immune cell targets, and the subsequent development of therapies based on these findings.
OBT's approach, based on our proprietary immune-oncology and antibody-drug conjugate pipelines, is to re-engage and recruit the body's immune system to attack cancer cells. We are therefore able to provide targeted treatment strategies to patients most in need, including those who have failed to respond to conventional treatments. Our first therapy, a drug for relapsed/refractory Acute Myeloid Leukemia (AML), entered Ph I testing in Europe in 2012 in collaboration with the Menarini group.
To help bring about this much awaited transformation in the cancer therapy landscape, we have built one of the world’s largest integrated oncology immune cell surface protein libraries. This, together with our dedicated team of international immuno-oncology experts and our broad clinical alliances, have led to our discovery of multiple never-before identified cancer-immune cell targets, and the subsequent development of therapies based on these findings.
|
OVERVIEW
Fully funded clinical ADC/C pipeline Portfolio approach – up to five programs De-risked to Ph II/ POC through partnership Broader innovative IO pipeline Critical discovery: Major novel immune escape mechanism Discovery of novel IO receptors & ligands 300+ patents 100 granted |
MILESTONES
1st ADCC Monoclonal Antibody in AML MEN1112 - PhI ongoing 2nd ADC in TNBC, DLBCL & other MEN1309 - PhI initiated Upto €800 million investment from Menarini Ltd. Clincal testing of upto 5 mAbs OBT retains US & Japanese rights IO pipeline Multiple programs in pre-clinical development |
GLOBAL HEADQUARTERS94a Innovation Drive
Milton Park Abingdon OX14 4RZ UK +44 (0) 1235 861770 |
US OPERATIONSSan Jose Biocenter
5941 Optical Court San Jose, CA 95138 USA +1-408-960-7461 |
